Screener
Avalo Therapeutics AVTX Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Other (expense) income: | ||||
| Change in fair value of derivative liability | (1,010) | (2,530) | (530) | (2,150) |
| Change in fair value of contingent consideration | (6,574) | — | (6,574) | — |
| Interest income, net | 2,761 | 1,097 | 3,564 | 2,244 |
| Total other (expense) income, net | (4,823) | (1,433) | (3,540) | 94 |
| Loss before taxes | (36,340) | (20,749) | (55,959) | (33,890) |
| Income tax expense | 18 | 16 | 29 | 24 |
| Net loss | $(36,358) | $(20,765) | $(55,988) | $(33,914) |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's interest expense?
- Avalo Therapeutics (AVTX) reported interest expense of $2.76M in Q2 2026.
- How has Avalo Therapeutics's interest expense changed year-over-year?
- Avalo Therapeutics's interest expense increased by 151.7% year-over-year, from $1.1M to $2.76M.
- What is the long-term trend for Avalo Therapeutics's interest expense?
- Over 4 years (2021 to 2025), Avalo Therapeutics's interest expense has grown at a 16.1% compound annual growth rate (CAGR), from -$2.39M to $4.35M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Avalo Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude